Table 2.
Clinical characteristics of the enrolled subjects in the second cohort.
| Variable | Medication group | Control group | p-value |
|---|---|---|---|
| (n = 40) | (n = 50) | ||
| Male/Female (n/n) | 17/23 | 20/30 | 0.24 |
| Age (years) | 50.86 ± 12.30 | 46.36 ± 10.25 | 0.06 |
| Body mass index (kg/m2) | 24.31 ± 2.34 | 23.74 ± 1.95 | 0.21 |
| Smoking status | |||
| Current smoker (%) | 6 (15%) | 4 (8%) | 0.33 |
| Former smoker (%) | 7 (18%) | 4 (8%) | 0.17 |
| Hypertension history, n (%) | 17 (43%) | 8 (16%) | <0.01∗∗ |
| Hyperlipidaemia history, n (%) | 25 (63%) | 7 (14%) | <0.01∗∗ |
| Diabetes mellitus, n (%) | 4 (10%) | 3 (6%) | 0.70 |
| WBC (x 109 /L) | 5.75 ± 1.15 | 5.64 ± 1.24 | 0.67 |
| Heart rate (beats/minutes) | 72.42 ± 10.86 | 75.05 ± 9.62 | 0.23 |
| Cr (umol/L) | 73.25 ± 14.38 | 69.72 ± 13.40 | 0.23 |
| Medications | |||
| ACE inhibitors (%) | 14 (35%) | 5 (10%) | <0.01∗∗ |
| Beta-blockers (%) | 11 (28%) | 3 (6%) | <0.01∗∗ |
| Nitrates (%) | 5 (13%) | / | <0.01∗∗ |
| Statins (%) | 25 (63%) | 7 (14%) | <0.01∗∗ |
| Aspirin (%) | 10 (25%) | 3 (6%) | 0.02∗ |
| Clopidogrel (%) | 6 (15%) | / | <0.01∗∗ |
Data are shown as the mean ± SD, ∗p<0.05, ∗∗p<0.01 patients for medications versus control subjects.